Abstract: The development of radiolabeled peptide-based radiopharmaceuticals for imaging a variety of tumors has seen a new era in nuclear medicine.Recently, a number of radio-labeled somatostatin analogues have proven to be useful diagnostic imaging agents.The challenge is to synthesize a wide range of biologically active somatostatin analogue peptides without affecting their receptor binding properties, and label bioactive peptides with radionuclides with high specific activity without impairing the biological properties of the peptides.This review presents recent developments in radio-labeled somatostatin analogues and their pharmacokinetic properties, their potential as diagnostic imaging agents are also addressed.